BNP Paribas Financial Markets
CAPR icon

BNP Paribas Financial Markets’s Capricor Therapeutics CAPR Stock Holding History

BNP Paribas Financial Markets’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$255K Sell
10,579
-3,421
-24% -$104K ﹤0.01% 4121
2026
Q1 		$426K Buy
14,000
+5,706
+69% +$152K ﹤0.01% 3673
2025
Q4 		$239K Sell
8,294
-19,027
-70% -$248K ﹤0.01% 3975
2025
Q3 		$197K Sell
27,321
-9,077
-25% -$66.8K ﹤0.01% 4019
2025
Q2 		$361K Buy
36,398
+34,908
+2,343% +$369K ﹤0.01% 3511
2025
Q1 		$14.1K Sell
1,490
-2,132
-59% -$29.6K ﹤0.01% 4628
2024
Q4 		$50K Sell
3,622
-14,077
-80% -$247K ﹤0.01% 4435
2024
Q3 		$269K Buy
17,699
+15,872
+869% +$78.5K ﹤0.01% 3131
2024
Q2 		$8.71K Sell
1,827
-4,000
-69% -$22.3K ﹤0.01% 3736
2024
Q1 		$39.6K Buy
+5,827
New +$28.2K ﹤0.01% 3596
2022
Q4 		– Sell
-100
Closed -$600 – 4136
2022
Q3 		$600 Buy
+100
New +$511 ﹤0.01% 4498

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets's CAPR Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Capricor Therapeutics (CAPR) stake by 24% in Q2 2026, selling an estimated $104K and leaving 10,579 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #4121.

BNP Paribas Financial Markets first reported a position in CAPR in Q3 2022 and has held it in 11 quarters since. The position peaked at $426K in Q1 2026. 155 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • BNP Paribas Financial Markets held 10,579 shares of Capricor Therapeutics worth $255K as of Q2 2026.
  • BNP Paribas Financial Markets sold 3,421 Capricor Therapeutics shares in Q2 2026, an estimated $104K.
  • Capricor Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4121 holding.
  • BNP Paribas Financial Markets first reported a position in Capricor Therapeutics in Q3 2022 and has held it in 11 quarters since.
  • BNP Paribas Financial Markets's Capricor Therapeutics position peaked at $426K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.